Search research articles
Contact Us
Filters
Showing results (21-30 of 62) with videos related to
Page
of 7
Sort By:
British Journal of Haematology
|
May 14, 2022
Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia
Kai Zhu, Andrew Jamroz, Steven Huang, et al.
Critical Reviews in Oncology/Hematology
|
June 28, 2024
Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma
Davis Kuruvilla, Thien Huynh, Matthew Nester, et al.
Leukemia & Lymphoma
|
December 29, 2023
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis
Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, et al.
Blood Advances
|
July 23, 2024
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
Nilesh M Kalariya, Michelle A T Hildebrandt, Doris K Hansen, et al.
Frontiers in Oncology
|
November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease
Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.
Blood
|
July 14, 2019
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma
Ciara L Freeman, Robert Kridel, Alden A Moccia, et al.
Blood Advances
|
April 19, 2022
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
Diego Villa, Eva Hoster, Olivier Hermine, et al.
Leukemia
|
August 13, 2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
Ciara L Freeman, Prasath Pararajalingam, Ling Jin, et al.
Blood Advances
|
September 8, 2022
The outcome of older adults with classic Hodgkin lymphoma in British Columbia
Phoebe T M Cheng, Diego Villa, Alina S Gerrie, et al.
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 62) with videos related to
Sort By:
Page
of 7
British Journal of Haematology
|
May 14, 2022
Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia
Kai Zhu, Andrew Jamroz, Steven Huang, et al.
Critical Reviews in Oncology/Hematology
|
June 28, 2024
Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma
Davis Kuruvilla, Thien Huynh, Matthew Nester, et al.
Leukemia & Lymphoma
|
December 29, 2023
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis
Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, et al.
Blood Advances
|
July 23, 2024
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
Nilesh M Kalariya, Michelle A T Hildebrandt, Doris K Hansen, et al.
Frontiers in Oncology
|
November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease
Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.
Blood
|
July 14, 2019
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma
Ciara L Freeman, Robert Kridel, Alden A Moccia, et al.
Blood Advances
|
April 19, 2022
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
Diego Villa, Eva Hoster, Olivier Hermine, et al.
Leukemia
|
August 13, 2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
Ciara L Freeman, Prasath Pararajalingam, Ling Jin, et al.
Blood Advances
|
September 8, 2022
The outcome of older adults with classic Hodgkin lymphoma in British Columbia
Phoebe T M Cheng, Diego Villa, Alina S Gerrie, et al.
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Page
of 7